Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Evotec has signed within the 'NEU(2)-Consortium' framework and partially funded by the Federal Ministry of Education and Research (Bundesministerium fuer Bildung und Forschung - BMBF), an agreement with Merck KGaA, Darmstadt, Germany, to develop pre-clinical candidates for an undisclosed neurological disease.
Subscribe to our email newsletter
Evotec will provide drug discovery expertise covering in-vitro biology, medicinal chemistry and in-vitro and in-vivo pharmacology.
As part of the collaboration, Evotec will apply their integrated drug discovery expertise and technologies to identify interesting small molecules for the selected target.
Evotec and Merck said that under the contract, the molecules will be further optimised and progressed through lead optimisation to a pre-clinical candidate.
Evotec COO Mario Polywka said that they are proud to be part of the NEU(2) consortium and they are extremely pleased that Merck KGaA selected Evotec to collaborate on this interesting Drug Discovery Program which is a further recognition of the CNS disease expertise.
The NEU(2) consortium focuses on the development of novel therapies against neurological diseases with a specific focus on multiple sclerosis.